Alpha Tau Medical DRTS 深 滬
等待開盤 09-25 09:30:00 美东时间
14.64
+0.120
+0.83%
華盛通- 最 高14.72
- 今 開14.50
- 成交量 28.01万股
- 最 低 14.31
- 昨 收 14.52
- 總市值 13.52亿
- 52周最高 15.79
- 市盈率 靜 --
- 換手率 0.30%
- 52周最低 3.43
- 委 比 45.10%
- 總股本 9233.29万
- 歷史最高 20.65
- 量 比 0.49
- 振 幅 2.82%
- 歷史最低 1.75
- 每 手 1
- 風險率 3.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 大行齐上调AI应用股目标价！Adobe、CRWD等获看好，慧与科技绩后现多空分歧
今日重点评级关注：BTIG：维持Climb Bio"买入"评级，目标价从20美元升至32美元；巴克莱：维持Alpha Tau Medical"超配"评级，目标价从17美元升至30美元
09-04 12:30
Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions
Alpha Tau Medical Ltd. announced the completion of patient enrollment in its IMPACT study, a multicenter pilot evaluating intratumoral Alpha DaRT in combination with first-line chemotherapy for pancreatic cancer. The study expanded enrollment three times, reaching 48 patients, driven by high demand. Initial data is expected in early 2027, informing future pivotal studies. This marks a significant milestone in advancing treatment for pancreatic ca...
08-31 12:00
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
HC Wainwright & Co. Maintains Buy on Alpha Tau Medical, Raises Price Target to $16
HC Wainwright & Co. analyst Yi Chen maintains Alpha Tau Medical (NASDAQ:DRTS) with a Buy and raises the price target from $15 to $16.
08-11 22:58
Alpha Tau Medical Q2 EPS $(0.50) Misses $(0.14) Estimate
Alpha Tau Medical (NASDAQ:DRTS) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.14) by 257.14 percent. This is a 284.62 percent decrease over losses of $(0.13) per share from the same period last year.
08-11 04:39
Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Alpha Tau Medical Ltd. reported strong progress in Q2 2026, including 100% local disease control in recurrent glioblastoma trials, strategic collaboration with Tolmar for prostate cancer, and successful patient enrollment in key studies. The company also presented promising data in pancreatic and head & neck cancers, with a cash balance of $104.8 million supporting its growth.
08-10 20:01
美股大行评级 | 阿斯麦、贝莱德、纽约梅隆银行、信达思、JB亨特运输服务、美国制商银行、PNC金融服务集团等获多家大行集体上调目标价
今日重点评级关注：瑞杰金融：维持Electrovaya"强力买入"评级，目标价从14美元升至22美元；BTIG：维持vTv Therapeutics"买入"评级，目标价从49美元升至57美元
07-17 11:35
HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $15 price target.
07-16 22:14
Alpha Tau Medical Announces Success Treatment With Alpha DaRT Of First Glioblastoma Patient In Israel
Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the successful treatment with Alpha DaRT of the first glioblastoma patient in Israel, and the first ever outside of the United States, performed at ...
06-23 20:33
